Author:
Li Haixia,Li Jinghua,Gao Wanli,Zhen Cheng,Feng Limin
Abstract
Abstract
Background
Platinum resistance is an important cause of clinical recurrence and death for ovarian cancer. This study tries to systematically explore the molecular mechanisms for platinum resistance in ovarian cancer and identify regulatory genes and pathways via text mining and other methods.
Methods
Genes in abstracts of associated literatures were identified. Gene ontology and protein-protein interaction (PPI) network analysis were performed. Then co-occurrence between genes and ovarian cancer subtypes were carried out followed by cluster analysis.
Results
Genes with highest frequencies are mostly involved in DNA repair, apoptosis, metal transport and drug detoxification, which are closely related to platinum resistance. Gene ontology analysis confirms this result. Some proteins such as TP53, HSP90, ESR1, AKT1, BRCA1, EGFR and CTNNB1 work as hub nodes in PPI network. According to cluster analysis, specific genes were highlighted in each subtype of ovarian cancer, indicating that various subtypes may have different resistance mechanisms respectively.
Conclusions
Platinum resistance in ovarian cancer involves complicated signaling pathways and different subtypes may have specific mechanisms. Text mining, combined with other bio-information methods, is an effective way for systematic analysis.
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynaecology,Oncology
Reference49 articles.
1. Siegel R, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68(1):7–30.
2. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–29.
3. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. Focus on epithelial ovarian cancer. Cancer Cell. 2004;5(1):19–24.
4. Rossof AH, Talley RW, Stephens R, Thigpen T, Samson MK, Groppe C Jr. el. Phase II evaluation of cis-dichlorodiammineplatinum (II) in advanced malignancies of the genitourinary and gynecologic organs: a southwest oncology group study. Cancer Treat Rep. 1979;63(9–10):1557–64.
5. Thigpen T, Shingleton H, Homesley H, LaGasse L, Blessing J. cis-Dichlorodiammineplatinum (II) in the treatment of gynecologic malignancies: phase II trials by the gynecologic oncology group. Cancer Treat Rep. 1979;63(9–10):1549–55.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献